BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Facon T, Venner CP, Bahlis NJ, Offner F, White DJ, Karlin L, Benboubker L, Rigaudeau S, Rodon P, Voog E, Yoon SS, Suzuki K, Shibayama H, Zhang X, Twumasi-Ankrah P, Yung G, Rifkin RM, Moreau P, Lonial S, Kumar SK, Richardson PG, Rajkumar SV. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 2021;137:3616-28. [PMID: 33763699 DOI: 10.1182/blood.2020008787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Suichi T, Misawa S, Sekiguchi Y, Shibuya K, Nakamura K, Kano H, Aotsuka Y, Otani R, Morooka M, Tsukamoto S, Takeda Y, Mimura N, Ohwada C, Sakaida E, Kuwabara S. Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome. Intern Med 2022;61:2567-72. [PMID: 36047093 DOI: 10.2169/internalmedicine.8786-21] [Reference Citation Analysis]
2 Huo Z, Chen F, Liu P, Luo Z. Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China-Compared with bortezomib/lenalidomide/dexamethasone. Cancer Med 2022. [PMID: 36052569 DOI: 10.1002/cam4.5198] [Reference Citation Analysis]
3 Suzuki T, Maruyama D, Iida S, Nagai H. Recent advances in the management of older adults with newly diagnosed multiple myeloma in Japan. Jpn J Clin Oncol 2022:hyac111. [PMID: 35830865 DOI: 10.1093/jjco/hyac111] [Reference Citation Analysis]
4 Rafae A, Ehsan H, Wahab A, Khan SI, Khan I, Ashraf S, Ali S, Khalid F, Neupane K, Valent J, Khouri J, Samaras C, Mazzoni S, Anwer F. Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients. Crit Rev Oncol Hematol 2022;176:103744. [PMID: 35717005 DOI: 10.1016/j.critrevonc.2022.103744] [Reference Citation Analysis]
5 Yang P, Qu Y, Wang M, Chu B, Chen W, Zheng Y, Niu T, Qian Z. Pathogenesis and treatment of multiple myeloma. MedComm (2020) 2022;3:e146. [PMID: 35665368 DOI: 10.1002/mco2.146] [Reference Citation Analysis]
6 Bertamini L, Bertuglia G, Oliva S. Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results. Front Oncol 2022;12:844779. [PMID: 35646628 DOI: 10.3389/fonc.2022.844779] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sellin M, Berg S, Hagen P, Zhang J. The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma. Transl Oncol 2022;22:101448. [PMID: 35660848 DOI: 10.1016/j.tranon.2022.101448] [Reference Citation Analysis]
8 Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 2022. [PMID: 35560063 DOI: 10.1002/ajh.26590] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
9 Hanamura I. Multiple myeloma with high-risk cytogenetics and its treatment approach. Int J Hematol 2022. [PMID: 35534749 DOI: 10.1007/s12185-022-03353-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Gupta RK, Gupta A, Hillengass J, Holstein SA, Suman VJ, Taneja A, McCarthy PL. A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022. Expert Rev Anticancer Ther 2022;:1-13. [PMID: 35503516 DOI: 10.1080/14737140.2022.2069564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Goel U, Usmani S, Kumar S. Current approaches to management of newly diagnosed multiple myeloma. Am J Hematol 2022;97 Suppl 1:S3-S25. [PMID: 35234302 DOI: 10.1002/ajh.26512] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
12 Touzeau C. Elotuzumab: no benefit for older patients with newly diagnosed multiple myeloma. The Lancet Haematology 2022. [DOI: 10.1016/s2352-3026(22)00132-6] [Reference Citation Analysis]
13 Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos M, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou Y, Ganetsky A, Popa Mckiver M, Lonial S, Weisel K, Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos M, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou Y, Ganetsky A, Popa Mckiver M, Lonial S, Weisel K, Sandhu I, Podhorecka M, Palumbo A, Shacham-abulafia A, Vaxman I, Shpilberg O, Besemer B, Martelli M, Foà R, De Fabritiis P, Caravita di Toritto T, Gheorghita E, Oriol A, Rowlings P, Emanuele A, Carella AM, Offidani M, Bladé J, Casado LF, Oakervee H, Panelli V, Meza L, Kühr T, Granell M, Benson D, Nair R, Holden V, Reeves J, Eek RW, Walker PA, Catalano J, Rosta A, Lech-marańda E, Samaras C, Reiman A, Weaver R, Acs P, Grigg A, De Prijck B, Louzada M, Minuk L, Sebag M, Klausmann M, Welslau M, Hellmann A, Danaila C, Becker P, Bensinger W, Porterfield B, Modiano M, Schultz SM, Manges R, Lee HC, Gray JX, Wright MP, Vekemans M, Hamed A, Gasztonyi Z, Mikala G, Masszi T, Gamberi B, Kuliczkowski K, Usnarska-zubkiewicz L, Bengoechea E, Gutiérrez MA, García MT, San-miguel J, Driessen C, Behl R, Brenner W, Gray C, Hansen V, Moezi M, Cortes HV, Yen C, Gressot L, Horvath N, D'rozario JM, Latimer M, Kyrtsonis M, Chubar E, Mittelman M, Baldini L, Tosi P, Vacca A, Jędrzejczak WW, Robak T, Lahuerta JJ, Carney J, Chen F, Hirsch R, Ruiz M, Alencar A, Jagasia M, Kasbari S, Kuriakose P, Mahmood A, Chaudhry M, Cohen G, Noga S, Roa S, Jakubowiak A, Rosenbaum C, Delforge M, Delrieu V, Doyen C, Dries D, Demuynck H, Schots R, Maisnar V, Blau IW, Dürk HA, Kerkhoff A, Kropff M, Munder M, Röllig C, Scheid C, Symeonidis AS, Illés Á, Coyne M, O'gorman P, Hayden P, O'dwyer M, Ben-yehuda D, Braester A, Nemets A, Lugassy G, Cohen Y, Rahimi-levene N, Bosi A, Pezzatti S, Rossini F, Pogliani EM, Pinto A, Komarnicki M, Borsaru G, Stoia R, Afanasyev B, Goñi MA, Carboneras AV, Ali S, Rubenstein SE, Caputto S, Cosgriff T, Fanning S, Khojasteh A, Liman A, Malcolm A, Vrindavanam N, Patel R, Belani R, Shieh M, Stockerl-goldstein K, Strnad C, Stuart R, Chhabra S, Costa L, Jhangiani H, Augustson B, Filshie R, Johnston A, Hertzberg MS, Mineur P, Fox S, Kotb R, Dao V, Leblanc R, Gregora E, Brioli A, Mügge L, Hänel M, Langer C, Kapsali E, Briasoulis E, Kyriakou D, Hardan I, Horowitz NA, Clotilde C, Fabbiano F, Castagnari B, Ciceri F, Musuraca G, Deptała A, Kłoczko J, Balea M, Vladareanu A, Rossiev V, Alegre A, Encinas C, Gayoso J, Pabst T, Rabin N, Arledge S, Cabanillas F, Catlett J, Chidiac T, Clarkson D, Dhodapkar M, Geils G, Khan CM, Sahovic E, Khasawneh M, Sehgal R, Ballester O, Levy M, Fay J, Liem K, Lunning M, Vose J, Faber E, Macfarlane D, Hohl R, Mahmood T, Bhaskar B, Mims M, Oliff I, Paner A, Maciejewski J, Padmanabhan A, Richard R, Sanyal A, Schiller G, Staszewski H, Stevens D, Vaughn C, Windsor K. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. The Lancet Haematology 2022. [DOI: 10.1016/s2352-3026(22)00103-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
14 Tacchetti P, Rocchi S, Barbato S, Zamagni E, Pantani L, Mancuso K, Rizzello I, Cavo M. Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients. Expert Rev Hematol 2021;:1-14. [PMID: 34602012 DOI: 10.1080/17474086.2021.1983426] [Reference Citation Analysis]
15 Harousseau JL, Mohty M. Up-front ixazomib in older patients with myeloma. Blood 2021;137:3584-6. [PMID: 34196682 DOI: 10.1182/blood.2021011262] [Reference Citation Analysis]